What Is Acinetobacter Baumannii?

Acinetobacter baumannii (scientific name: Acinetobacter baumannii, commonly known as AB bacteria), also known as Acinetobacter baumannii, is a Gram-negative bacterium and is a conditional pathogenic bacteria that strictly aerobic and non-lactose fermentation [, without Flagellum is not very mobile, but it has strong vitality and can exist widely in nature. This bacterium is a common type of hospital infection among Acinetobacter bacteria, and it is also a pathogen of aquaculture animals. It usually causes bacteremia, pneumonia, meningitis, peritonitis, endocarditis, and urinary tract and skin infections. Acinetobacter baumannii has become a major source of nosocomial infections, especially in intensive care units. Due to the abuse of antibiotics, the pathogen caused Acinetobacter baumannii to become resistant, and became "multi-drug resistant Acinetobacter baumannii." Currently, the only way to combat multi-drug resistant Acinetobacter baumannii is to use back-line antibiotics such as tigmycin. ^[1]

Bowman stays still

Bowman stays still

At present, Acinetobacter spp. Contains 55 species, mainly A. calcoacet

Do not move

I. Pulmonary infection In terms of the source of infection, there are both exogenous and endogenous infections. Inhalation of oropharyngeal bacteria is likely to be the main pathogenesis of endogenous infections. Often

The biochemical identification was mainly based on the API-20NE system, and 5 necessary tests were supplemented. The results show that 4 kinds of immobility

Bowman stays still

With the rapid development of medical technology, the level of treatment of diseases, especially critical diseases, has been continuously improved.

Acinetobacter baumannii may be a prelude to the "superbug" pandemic in Japan

Multi-drug resistant "super bacteria" are currently showing signs of expanding infection in Japan. Following a suspected large-scale infection of inpatients with "super bacteria" at the Affiliated Hospital of the Department of Medicine of Teikyo University in Japan in early September 2010, a new type of "super bacteria" was detected at the Dokkyo Medical University Hospital in Tochigi. The Japanese government decided on September 7, 2010 to require all medical institutions across the country to report cases of infection as soon as they are found, and to conduct a nationwide investigation on the infection status of new "super bacteria" within one week.

The Japanese government has discovered a large-scale bacterial infection in a hospital affiliated with the Department of Medicine of Teikyo University in Tokyo, Japan. This bacterium is called "multidrug-resistant Acinetobacter baumannii" and it does not have much effect on healthy people, but if people with low immunity are infected with this bacterium, it will produce complications such as pneumonia and sepsis. And even cause death, this "superbug" is resistant to almost all antibiotics.

As early as August 2009, the first infected person had appeared in the Affiliated Hospital of the Department of Medicine of Dijing University. However, the hospital reported the infection to the relevant departments on September 2, 2010. By September 1, 2010, the number of infections had risen to 46, of which 27 had died. Of the deceased, 9 had determined that the cause of death was related to the infection. In response to the large-scale bacterial infection in the hospital affiliated to the Department of Medicine of Teikyo University, the Japanese Ministry of Health, Labour and Welfare established a special emergency response team on the 5th, and on the 6th conducted an on-site investigation into the adequacy of the epidemic prevention system in the hospital of the Ministry of Health and Medical Technology. An investigation found that although the hospital received a notification from the Japanese government to report infection cases in January 2009, all medical staff at the hospital were unaware and there were problems with the contact mechanism.

According to reports, the neighboring hospital in Setagaya-ku, Tokyo, reported another 8 cases of infection on September 7, 2010. Two of the deaths were suspected to be related to bacterial infection. After investigation, it was found that the first infected patient who appeared in the affiliated hospital of the Department of Medicine of Dijing University in 2009 did not go abroad, and the infection route may come from China. Therefore, Japanese experts warn that Acinetobacter baumannii may have spread throughout the country, and it may be a prelude to the pandemic of "super bacteria" in Japan. The government should strengthen its surveillance system and make every effort to prevent the spread of infection.

Following a large-scale bacterial infection problem in the affiliated hospital of the Department of Medicine of Teikyo University, a new type of "super bacteria" was detected on September 6th at the Medical Association Hospital of Tokkyo in Tochigi. This bacterium is an E. coli with the NDM-1 gene, and it can resist almost all antibiotics under the action of the NDM-1 gene. If patients with low immunity are infected with the bacteria, they may spread throughout the body, cause complications such as sepsis, and even cause death. This gene is highly contagious, and because E. coli is widely present in daily life, it is also very likely to be transmitted between ordinary healthy people. This is the first time that a "superbug" carrying the NDM-1 gene has been discovered in Japan.

The emergence of "super bacteria" in Japan has drawn great attention from the government. Relevant experts point out that because the new type of "super bacteria" is highly resistant and infectious, the bacteria's drug resistance genes may also be transferred from E. coli to other types of bacteria, making other bacteria resistant. If the "superbug" resistance gene is transferred to dangerous bacteria such as Salmonella or Shigella, the consequences will be unimaginable.

The long-term wife of Japan s Minister of Health, Labour and Welfare told the media after a cabinet meeting on September 7 that the Japanese government will launch an investigation into hospitals across the country. Although large hospitals in Japan have the ability to analyze bacteria alone, the Ministry of Health, Labour and Welfare requires that all hospitals across the country should submit bacteria with multidrug resistance to the National Institute of Infectious Diseases for testing immediately. In addition, the Japanese government will set up a working group of infectious disease experts to discuss specific prevention and control measures.